Advertisement

Drug Safety

, Volume 27, Issue 3, pp 145–172 | Cite as

Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes

Potential Tool for Improving Clinical Drug Development and Prescribing
  • Rashmi R. Shah
Leading Article

Abstract

Drug-induced torsade de pointes (TdP) has proved to be a significant iatrogenic cause of morbidity and mortality and a major reason for the withdrawal of a number of drugs from the market in recent times. Enzymes that metabolise many of these drugs and the potassium channels that are responsible for cardiac repolarisation display genetic polymorphisms. Anecdotal reports have suggested that in many cases of drug-induced TdP, there may be a concealed genetic defect of either these enzymes or the potassium channels, giving rise to either high plasma drug concentrations or diminished cardiac repolarisation reserve, respectively. The presence of either of these genetic defects may predispose a patient to TdP, a potentially fatal adverse reaction, even at therapeutic dosages of QT-prolonging drugs and in the absence of other risk factors. Advances in pharmacogenetics of drug metabolising enzymes and pharmacological targets, together with the prospects of rapid and inexpensive genotyping procedures, promise to individualise and improve the benefit/risk ratio of therapy with drugs that have the potential to cause TdP. The qualitative and the quantitative contributions of these genetic defects in clinical cases of TdP are unclear because not all of the patients with TdP are routinely genotyped and some relevant genetic mutations still remain to be discovered.

There are regulatory guidelines that recommend strategies aimed at uncovering the risk of TdP associated with new chemical entities during their development. There are also a number of guidelines that recommend integrating pharmacogenetics in this process. This paper proposes a strategy for integrating pharmacogenetics into drug development programmes to optimise association studies correlating genetic traits and endpoints of clinical interest, namely failure of efficacy or development of repolarisation abnormalities. Until pharmacogenetics is carefully integrated into all phases of development of QT-prolonging drugs and large-scale studies are undertaken during their post-marketing use to determine the genetic components involved in induction of TdP, routine genotyping of patients remains unrealistic.

Even without this pharmacogenetic data, the clinical risk of TdP can already be greatly minimised. Clinically, a substantial proportion of cases of TdP are due to the use of either high or usual dosages of drugs with potential to cause TdP in the presence of factors that inhibit drug metabolism. Therefore, choosing the lowest effective dose and identifying patients with these non-genetic risk factors are important means of minimising the risk of TdP. In view of the common secondary pharmacology shared by these drugs, a standard set of contraindications and warnings have evolved over the last decade. These include factors responsible for pharmacokinetic or pharmacodynamic drug interactions. Among the latter, the more important ones are bradycardia, electrolyte imbalance, cardiac disease and co-administration of two or more QT-prolonging drugs.

In principle, if large scale prospective studies can demonstrate a substantial genetic component, pharmacogenetically driven prescribing ought to reduce the risk further. However, any potential benefits of pharmacogenetics will be squandered without any reduction in the clinical risk of TdP if physicians do not follow prescribing and monitoring recommendations.

Keywords

Cisapride Terfenadine Tolterodine Thioridazine Astemizole 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The views expressed in this paper are those of the author and do not necessarily represent the views or the opinions of Medicines and Healthcare products Regulatory Agency, other regulatory authorities or any of their advisory committees.

The author has not received any funding from any source in the preparation of this manuscript. There are no conflicts of interest directly relevant to the contents of this review.

The author would like to thank Professor Joel Morganroth (PA, USA) and Professor David Goldstein (London, UK) for their very helpful and constructive comments during the preparation of this paper.

References

  1. 1.
    International Conference on Harmonisation (ICH) Guidelines. Note for Guidance on Dose Response Information to Support Drug Registration. (CPMP/ICH/378/95). Committee for Proprietary Medicinal Products, London, May 1995 [online]. Available from URL: http://www.emea.eu.int/htms/human/ich/efficacy/ichfin.htm [Accessed 2003 Apr 15]
  2. 2.
    McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41: 101–21PubMedCrossRefGoogle Scholar
  3. 3.
    Kalow W. Pharmacogenetics: heredity and the response to drugs. Philadelphia (PA): WB Saunders, 1962Google Scholar
  4. 4.
    Vogel F. Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd 1959; 12: 52-125Google Scholar
  5. 5.
    Shah RR. Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 2002; 16: 119–24PubMedCrossRefGoogle Scholar
  6. 6.
    Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 2002; 16: 147–56PubMedCrossRefGoogle Scholar
  7. 7.
    Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188–202PubMedCrossRefGoogle Scholar
  8. 8.
    Salle P, Rey JL, Bernasconi P, et al. Torsades de pointe. Apropos of 60 cases [in French]. Ann Cardiol Angeiol (Paris) 1985; 34: 381–8Google Scholar
  9. 9.
    Milon D, Daubert JC, Saint-Marc C, et al. Torsade de pointes: apropos of 54 cases [in French]. Ann Fr Anesth Reanim 1982; 1: 513–20PubMedCrossRefGoogle Scholar
  10. 10.
    Fung MC, Hsiao-hui Wu H, Kwong K, et al. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past 3 decades: 1969-1998 [abstract]. Pharmacoepidemiol Drug Saf 2000; 9Suppl. 1: S24–5Google Scholar
  11. 11.
    The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products (CPMP/986/96). Committee for Proprietary Medicinal Products, London, Dec 1997 [online]. Available from URL: http://www.emea.eu.int/htms/human/swp/swpptc.htm [Accessed 2003 Apr 15]
  12. 12.
    Priori SG, Barhanin J, Hauer RNW, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management. Eur Heart J 1999; 20: 174–95PubMedCrossRefGoogle Scholar
  13. 13.
    Bauman JL, Bauernfeind RA, Hoff JV, et al. Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J 1984; 107: 425–30PubMedCrossRefGoogle Scholar
  14. 14.
    MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993; 72: 44A–50APubMedCrossRefGoogle Scholar
  15. 15.
    McKibbin JK, Pocock WA, Barlow JB, et al. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 1984; 2: 157–62CrossRefGoogle Scholar
  16. 16.
    Ben-David J, Zipes DP. Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early after depolarizations and ventricular tachyarrhythmias in dogs. Circulation 1990; 82: 225–33PubMedCrossRefGoogle Scholar
  17. 17.
    Lu HR, Remeysen P, De Clerck F. Nonselective I (Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation. J Cardiovasc Pharmacol 2000; 36: 728–36PubMedCrossRefGoogle Scholar
  18. 18.
    Furushima H, Chinushi M, Washizuka T, et al. Role of α1-blockade in congenital long QT syndrome: investigation by exercise stress test. Jpn Circ J 2001; 65: 654–8PubMedCrossRefGoogle Scholar
  19. 19.
    Noda T, Takaki H, Kurita T, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 2002; 23: 975–83PubMedCrossRefGoogle Scholar
  20. 20.
    Prenylamine withdrawn in UK. Scrip 1988; 1300: 26Google Scholar
  21. 21.
    Price-Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a British white population. J Med Genet 1980; 17: 102–5CrossRefGoogle Scholar
  22. 22.
    Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003; 17: 27–41PubMedCrossRefGoogle Scholar
  23. 23.
    Dahl M-L. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453–70PubMedCrossRefGoogle Scholar
  24. 24.
    Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342–9PubMedCrossRefGoogle Scholar
  25. 25.
    Human Cytochrome P450 (CYP) Allele Nomenclature Committee [online]. Available from URL: http://www.imm.ki.se/CYPalleles/ [Accessed 2003 Apr 15]
  26. 26.
    Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516–20PubMedGoogle Scholar
  27. 27.
    Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414–23PubMedGoogle Scholar
  28. 28.
    Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210–58PubMedCrossRefGoogle Scholar
  29. 29.
    Idle JR, Smith RL. The debrisoquine hydroxylation gene: a gene of multiple consequences. In: Lemberger L, Reidenberg MM, editors. Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics. Bethesda (MD): American Society for Pharmacology and Experimental Therapeutics, 1984: 148–64Google Scholar
  30. 30.
    Idle JR, Mahgoub A, Lancaster R, et al. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci 1978; 22: 979–83PubMedCrossRefGoogle Scholar
  31. 31.
    Eichelbaum M. Polymorphic oxidation of debrisoquine and sparteine. In: Kalow W, Goedde HW, Agarwal DP, editors. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R. Liss Inc., 1986: 157–67Google Scholar
  32. 32.
    Pollock BG, Mulsant BH, Sweet RA, et al. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31: 327–31PubMedGoogle Scholar
  33. 33.
    Beckmann J, Hertrampf R, Gundert-Remy U, et al. Is there a genetic factor in flecainide toxicity? Br Med J 1988; 297: 1316CrossRefGoogle Scholar
  34. 34.
    Shah RR, Oates NS, Idle JR, et al. Impaired oxidation of debrisoquine in patients with perhexiline-neuropathy. Br Med J 1982; 284: 295–9CrossRefGoogle Scholar
  35. 35.
    Morgan MY, Reshef R, Shah RR, et al. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25: 1057–64PubMedCrossRefGoogle Scholar
  36. 36.
    Oates NS, Shah RR, Idle JR, et al. Phenformin-induced lactic acidosis associated with impaired debrisoquine hydroxylation. Lancet 1981; I: 837–8CrossRefGoogle Scholar
  37. 37.
    Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785–91PubMedCrossRefGoogle Scholar
  38. 38.
    Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 1990; 322: 1764–9PubMedCrossRefGoogle Scholar
  39. 39.
    Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 1558–60PubMedCrossRefGoogle Scholar
  40. 40.
    Bertilsson L, Mellstrom B, Sjoqvist F, et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1981; I: 560–1CrossRefGoogle Scholar
  41. 41.
    Billon N, Funck-Brentano C, Cohen A, et al. Influence of CYP2D6 genetic polymorphism on the pharmacokinetics and pharmacodynamic effects of terikalant, a new K+ channel blocker [abstract]. Fundam Clin Pharmacol 1995; 9: 88Google Scholar
  42. 42.
    Gross AS, Phillips AC, Rieutord A, et al. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br J Clin Pharmacol 1996; 41: 311–7PubMedCrossRefGoogle Scholar
  43. 43.
    Flockhart DA, Clauw DJ, Sale EB, et al. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994; 56: 398–405PubMedCrossRefGoogle Scholar
  44. 44.
    Pierce DM, Smith SE, Franklin RA. The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. Eur J Clin Pharmacol 1987; 33: 59–65PubMedCrossRefGoogle Scholar
  45. 45.
    Llerena A, Berecz R, de la Rubia A, et al. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 2002; 16: 361–4PubMedCrossRefGoogle Scholar
  46. 46.
    Poulsen L, Brosen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289–95PubMedCrossRefGoogle Scholar
  47. 47.
    Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636–44PubMedCrossRefGoogle Scholar
  48. 48.
    Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7: 375–9PubMedCrossRefGoogle Scholar
  49. 49.
    Winkle RA, Mason JW, Griffin JC, et al. Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 1981; 102: 857–64PubMedCrossRefGoogle Scholar
  50. 50.
    Dalen P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19: 543–4PubMedCrossRefGoogle Scholar
  51. 51.
    Dalen P, Dahl ML, Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444–52PubMedCrossRefGoogle Scholar
  52. 52.
    Laine K, Tybring G, Hartter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70: 327–35PubMedGoogle Scholar
  53. 53.
    Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P, et al. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months’ propafenone prophylactic treatment. Int J Clin Pharmacol Ther 2001; 39: 288–92PubMedGoogle Scholar
  54. 54.
    Lima JJ, Thomason DB, Mohamed MH, et al. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65: 519–25PubMedCrossRefGoogle Scholar
  55. 55.
    Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22: 168–70PubMedCrossRefGoogle Scholar
  56. 56.
    Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534–9PubMedCrossRefGoogle Scholar
  57. 57.
    Brodde OE, Buscher R, Tellkamp R, et al. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 2001; 103: 1048–50PubMedCrossRefGoogle Scholar
  58. 58.
    Weizman A, Weizman R. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics 2000; 1: 335–41PubMedCrossRefGoogle Scholar
  59. 59.
    Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508–11PubMedCrossRefGoogle Scholar
  60. 60.
    Kim DK, Lim SW, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215–9PubMedCrossRefGoogle Scholar
  61. 61.
    Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001; 104: 569–80PubMedCrossRefGoogle Scholar
  62. 62.
    Escande D. Pharmacogenetics of cardiac K+ channels. Eur J Pharmacol 2000; 410: 281–7PubMedCrossRefGoogle Scholar
  63. 63.
    Fedida D, Wible B, Wang Z, et al. Identity of a novel delayed rectifier potassium current from human heart with a cloned K+ channel current. Circ Res 1993; 73: 210–6PubMedCrossRefGoogle Scholar
  64. 64.
    Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmias. Cell 1999; 97: 175–87PubMedCrossRefGoogle Scholar
  65. 65.
    Barhanin J, Lasage F, Guillemare E, et al. KvLQT1 and IsK (minK) proteins associate to form the IKs cardiac potassium current. Nature 1996; 384: 78–80PubMedCrossRefGoogle Scholar
  66. 66.
    Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12: 17–23PubMedCrossRefGoogle Scholar
  67. 67.
    Mohler PJ, Schott J-J, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long QT cardiac arrhythmia and sudden death. Nature 2003; 421: 634–9PubMedCrossRefGoogle Scholar
  68. 68.
    Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866–74PubMedCrossRefGoogle Scholar
  69. 69.
    Zareba W, Moss AJ, Locati EH, et al. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol 2003; 42: 103–9PubMedCrossRefGoogle Scholar
  70. 70.
    Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1 and KCNE2. Circulation 2000; 102: 1178–85PubMedCrossRefGoogle Scholar
  71. 71.
    Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002; 105: 794–9PubMedCrossRefGoogle Scholar
  72. 72.
    Bezzina CR, Verkerk AO, Busjahn A, et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res 2003; 59: 27–36PubMedCrossRefGoogle Scholar
  73. 73.
    Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293–6PubMedCrossRefGoogle Scholar
  74. 74.
    Bezzina C, Veldkamp MW, van Den Berg MP, et al. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999; 85: 1206–13PubMedCrossRefGoogle Scholar
  75. 75.
    Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081–6PubMedCrossRefGoogle Scholar
  76. 76.
    Herfst LJ, Potet F, Bezzina CR, et al. Na+ channel mutation leading to loss of function and non-progressive cardiac conduction defects. J Mol Cell Cardiol 2003; 35: 549–57PubMedCrossRefGoogle Scholar
  77. 77.
    Veldkamp MW, Wilders R, Baartscheer A, et al. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res 2003; 92: 976–83PubMedCrossRefGoogle Scholar
  78. 78.
    Bezzina CR, Rook MB, Groenewegen WA, et al. Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ Res 2003; 92: 159–68PubMedCrossRefGoogle Scholar
  79. 79.
    An overview of the inherited long QT syndrome and sample materials [online]. Available from URL: http://www.sads.org/LQTS.html [Accessed 2004 Jan 20]
  80. 80.
    Vincent GM, Timothy KW, Leppert M, et al. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327: 846–52PubMedCrossRefGoogle Scholar
  81. 81.
    Saarinen K, Swan H, Kainulainen K, et al. Molecular genetics of the long QT syndrome: two novel mutations of the KVLQT1 gene and phenotypic expression of the mutant gene in a large kindred. Hum Mutat 1998; 11: 158–65PubMedCrossRefGoogle Scholar
  82. 82.
    Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999; 99: 529–33PubMedCrossRefGoogle Scholar
  83. 83.
    Streetman DS, Bertino Jr JS, Nafziger AN. Phenotyping of drug metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187–216PubMedCrossRefGoogle Scholar
  84. 84.
    Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long QT syndrome. J Am Coll Cardiol 2003; 41: 633–42PubMedCrossRefGoogle Scholar
  85. 85.
    Glassman AH, Bigger Jr JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–82PubMedCrossRefGoogle Scholar
  86. 86.
    Thioridazine and severe cardiac arrhythmia. Prescrire Int 2001; 10 (56): 183–4Google Scholar
  87. 87.
    Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996; 60: 543–53PubMedCrossRefGoogle Scholar
  88. 88.
    von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234–40CrossRefGoogle Scholar
  89. 89.
    Llerena A, Berecz R, de la Rubia A, et al. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 2000; 22: 397–401PubMedCrossRefGoogle Scholar
  90. 90.
    Eap CB, Guentert TW, Schäublin-Loidl M, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322–31PubMedCrossRefGoogle Scholar
  91. 91.
    Carrillo JA, Ramos SI, Herraiz AG, et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 1999; 19: 494–9PubMedCrossRefGoogle Scholar
  92. 92.
    Meyer JW, Woggon B, Baumann P, et al. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990; 39: 613–4PubMedCrossRefGoogle Scholar
  93. 93.
    Thanaccody R, Daly AK, Thomas SH. Influence of CYP2D6 genotype on the QTc interval and plasma concentrations of thioridazine and its metabolites in psychiatric patients taking chronic therapy [abstract]. Clin Pharmacol Ther 2003; 73: 77CrossRefGoogle Scholar
  94. 94.
    Wibell L. Terodiline in angina pectoris: a controlled study of a new drug. Acta Soc Med Ups 1968; 73: 75–80PubMedGoogle Scholar
  95. 95.
    Cattini RA, Makin HL, Trafford DJ, et al. An apparent fatal overdose of terodiline. J Anal Toxicol 1989; 13: 110–2PubMedGoogle Scholar
  96. 96.
    Davis SW, Brecker SJ, Stevenson RN. Terodiline for treating detrusor instability in elderly patients [letter]. Br Med J 1991; 302: 1276CrossRefGoogle Scholar
  97. 97.
    McLeod AA, Thorogood S, Barnett S. Torsade de pointes complicating treatment with terodiline [letter]. Br Med J 1991; 302: 1469CrossRefGoogle Scholar
  98. 98.
    Connolly MJ, Astridge PS, White EG, et al. Torsade de pointes, ventricular tachycardia and terodiline. Lancet 1991; 338: 344–5PubMedCrossRefGoogle Scholar
  99. 99.
    Andrews NP, Bevan J. Torsade de pointes and terodiline. Lancet 1991; 338: 633Google Scholar
  100. 100.
    Committee on Safety of Medicines, London. Withdrawal of terodiline. Current Problems 1991; 32: 1–2Google Scholar
  101. 101.
    Hartigan-Go K, Bateman ND, Daly AK, et al. Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 1996; 60: 89–98PubMedCrossRefGoogle Scholar
  102. 102.
    Hallén B, Gabrielsson J, Palmér L, et al. Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. Pharmacol Toxicol 1993; 73: 153–8PubMedCrossRefGoogle Scholar
  103. 103.
    Thomas SHL, Hartigan-Go K. Disposition of R(+)- and S(−)-terodiline in healthy man [abstract]. Clin Pharmacol Ther 1996; 59: 160CrossRefGoogle Scholar
  104. 104.
    Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 289–93PubMedGoogle Scholar
  105. 105.
    Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998; 63: 529–39PubMedCrossRefGoogle Scholar
  106. 106.
    Brynne N, Forslund C, Hallen B, et al. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999; 48: 564–72PubMedCrossRefGoogle Scholar
  107. 107.
    Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol 2000; 50: 77–80PubMedCrossRefGoogle Scholar
  108. 108.
    Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American Black populations. Pharmacogenetics 1997; 7: 59–64PubMedCrossRefGoogle Scholar
  109. 109.
    Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9: 539–49PubMedCrossRefGoogle Scholar
  110. 110.
    Shah RR. Withdrawal of terodiline: a tale of two toxicities. In: Mann RD, Andrews EB, editors. Pharmacovigilance. London: John Wiley & Sons Ltd, 2002: 135–54CrossRefGoogle Scholar
  111. 111.
    Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and Smephenytoin. Clin Pharmacol Ther 1992; 51: 388–97PubMedCrossRefGoogle Scholar
  112. 112.
    Tateishi T, Chida M, Ariyoshi N, et al. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999; 65: 570–5PubMedCrossRefGoogle Scholar
  113. 113.
    Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229–43PubMedCrossRefGoogle Scholar
  114. 114.
    Xie HG, Kim RB, Wood AJJ, et al. Molecular basis of ethnic differences in drug disposition and responses. Annu Rev Pharmacol Toxicol 2001; 41: 815–50PubMedCrossRefGoogle Scholar
  115. 115.
    Roe CM, Odell KW, Henderson RR. Concomitant use of antipsychotics and drugs that may prolong the QT interval. J Clin Psychopharmacol 2003; 23: 197–200PubMedCrossRefGoogle Scholar
  116. 116.
    Picard R, Auzepy P, Chauvin JP. Syncopes a repetition au cours d’un traitement prolonge par la prenylamine (Segontine 60) [letter]. Presse Med 1971; 79: 145PubMedGoogle Scholar
  117. 117.
    Hashimoto K, Nakagawa Y, Nabata H, et al. In vitro analysis of Ca-antagonistic effects of prenylamine as mechanisms for its cardiac actions. Arch Int Pharmacodyn Ther 1978; 231(2): 212–21PubMedGoogle Scholar
  118. 118.
    Bayer R, Schwarzmaier J, Pernice R. Basic mechanism underlying prenylamine-induced torsade de pointes: differences between prenylamine and fendiline due to basic actions of the isomers. Curr Med Res Opin 1988; 11: 254–72PubMedCrossRefGoogle Scholar
  119. 119.
    Geitl Y, Spahn H, Knauf H, et al. Single and multiple dose pharmacokinetics of R-(−)- and S-(+)-prenylamine in man. Eur J Clin Pharmacol 1990; 38: 587–93CrossRefGoogle Scholar
  120. 120.
    Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–8PubMedCrossRefGoogle Scholar
  121. 121.
    Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118–21PubMedCrossRefGoogle Scholar
  122. 122.
    Maginn M, Frederiksen K, Adamantidis MM, et al. The effects of sertindole and its metabolites on cardiac ion channels and action potentials [abstract]. J Physiol 2000; 525: 79PGoogle Scholar
  123. 123.
    Arnt J. Pharmacological differentiation of classical and novel antipsychotics. Int Clin Psychopharmacol 1998; 13Suppl. 3: S7–14PubMedCrossRefGoogle Scholar
  124. 124.
    Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002; 300: 64–71PubMedCrossRefGoogle Scholar
  125. 125.
    Toumi M, Auquier P, Francois C. The safety and tolerability of sertindole in a patient name use program [abstract]. Pharmacoepidemiol Drug Saf 2002; 11Suppl. 1: S115Google Scholar
  126. 126.
    Desai M, Tanus-Santos JE, Li L, et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J 2003; 3: 105–13PubMedCrossRefGoogle Scholar
  127. 127.
    Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590–7PubMedCrossRefGoogle Scholar
  128. 128.
    Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health 1998; 7: 547–57PubMedCrossRefGoogle Scholar
  129. 129.
    Hara M, Danilo Jr P, Rosen MR. Effects of gonadal steroids on ventricular repolarization and on the response to E4031. J Pharmacol Exp Ther 1998; 285: 1068–72PubMedGoogle Scholar
  130. 130.
    Lu HR, Marien R, Saels A, et al. Are there sex-specific differences in ventricular repolarization or in drug-induced early after depolarizations in isolated rabbit Purkinje fibers? J Cardiovasc Pharmacol 2000; 36: 132–9PubMedCrossRefGoogle Scholar
  131. 131.
    Shuba YM, Degtiar VE, Osipenko VN, et al. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol 2001; 62: 41–9PubMedCrossRefGoogle Scholar
  132. 132.
    Benton RE, Sale M, Flockhart DA, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 2000; 67: 413–8PubMedCrossRefGoogle Scholar
  133. 133.
    Benhorin J, Moss AJ, Bak M, et al. Variable expression of long QT syndrome among gene carriers from families with five different HERG mutations. Ann Noninvasive Electrocardiol 2002; 7: 40–6PubMedCrossRefGoogle Scholar
  134. 134.
    Dany F, Liozon F, Goudoud JC, et al. Severe ventricular arrhythmia following parenteral administration of vincamine. Predisposing factors in 6 cases [in French]. Arch Mal Coeur Vaiss 1980; 73: 298–306PubMedGoogle Scholar
  135. 135.
    Stratmann HG, Kennedy HL. Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987; 113: 1470–82PubMedCrossRefGoogle Scholar
  136. 136.
    Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997; 96: 2778–81PubMedCrossRefGoogle Scholar
  137. 137.
    Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054–6PubMedCrossRefGoogle Scholar
  138. 138.
    Wesche DL, Schuster BG, Wang W-X, et al. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther 2000; 67: 521–9PubMedCrossRefGoogle Scholar
  139. 139.
    Monlun E, Pillet O, Cochard JF, et al. Prolonged QT interval with halofantrine. Lancet 1993; 341: 1541–2PubMedGoogle Scholar
  140. 140.
    Castot A, Rapoport P, le Coz P. Prolonged QT interval with halofantrine. Lancet 1993, 341; 1541PubMedCrossRefGoogle Scholar
  141. 141.
    Piippo K, Holmstrom S, Swan H, et al. Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A. Am J Cardiol 2001; 87: 909–11PubMedCrossRefGoogle Scholar
  142. 142.
    Makita N, Horie M, Nakamura T, et al. Drug-induced long QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002; 106: 1269–74PubMedCrossRefGoogle Scholar
  143. 143.
    Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmias. Science 2002; 297: 1333–6PubMedCrossRefGoogle Scholar
  144. 144.
    Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000; 11: 691–6PubMedCrossRefGoogle Scholar
  145. 145.
    Koh KK, Rim MS, Yoon J, et al. Torsade de pointes by terfenadine in a patient with long QT syndrome. J Electrocardiol 1994; 27: 343–6PubMedCrossRefGoogle Scholar
  146. 146.
    Haverkamp W, Eckardt L, Monnig G, et al. Clinical aspects of ventricular arrhythmias associated with QT prolongation. Eur Heart J 2001; 3(Suppl. K): K81–K88Google Scholar
  147. 147.
    Wysowski DK, Corken A, Gallo-Torres H, et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698–703PubMedCrossRefGoogle Scholar
  148. 148.
    Severe cardiac arrhythmia on cisapride. Prescrire Int 2000; 9 (49): 144–5Google Scholar
  149. 149.
    Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000; 97: 10613–8PubMedCrossRefGoogle Scholar
  150. 150.
    Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105: 1943–8PubMedCrossRefGoogle Scholar
  151. 151.
    Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: the Survival With Oral d-Sotalol (SWORD) study. Lancet 1996; 348: 7–12PubMedCrossRefGoogle Scholar
  152. 152.
    Kanki H, Yang P, Xie HG, et al. Polymorphisms in betaadrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol 2002; 13: 252–6PubMedCrossRefGoogle Scholar
  153. 153.
    Itoh T, Kikuchi K, Odagawa Y, et al. Correlation of genetic etiology with response to beta-adrenergic blockade among symptomatic patients with familial long-QT syndrome. J Hum Genet 2001; 46: 38–40PubMedCrossRefGoogle Scholar
  154. 154.
    Charbit B, Becquemont L, Lepere B, et al. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther 2002; 72: 514–23PubMedCrossRefGoogle Scholar
  155. 155.
    Clifford CP, Adams DA, Murray S, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52: 311–5PubMedCrossRefGoogle Scholar
  156. 156.
    Kivisto KT, Lilja JJ, Backman JT, et al. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66: 448–53PubMedCrossRefGoogle Scholar
  157. 157.
    Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383–8PubMedCrossRefGoogle Scholar
  158. 158.
    Tanaka E. Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. J Clin Pharm Ther 1998; 23: 161–70PubMedCrossRefGoogle Scholar
  159. 159.
    Yang LQ, Li SJ, Cao YF, et al. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 2003; 9: 359–63PubMedGoogle Scholar
  160. 160.
    Lanthier PL, Reshef R, Shah RR, et al. Oxidation phenotyping in alcoholics with liver disease of varying severity. Alcohol Clin Exp Res 1984; 8: 435–41PubMedCrossRefGoogle Scholar
  161. 161.
    Adedoyin A, Arns PA, Richards WO, et al. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochrome P450 2C19 and 2D6. Clin Pharmacol Ther 1998; 64: 8–17PubMedCrossRefGoogle Scholar
  162. 162.
    Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6PubMedCrossRefGoogle Scholar
  163. 163.
    Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290–1PubMedCrossRefGoogle Scholar
  164. 164.
    Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322–6PubMedCrossRefGoogle Scholar
  165. 165.
    Näbauer M, Kääb S. Potassium channel down-regulation in heart failure. Cardiovasc Res 1998; 37: 324–34PubMedCrossRefGoogle Scholar
  166. 166.
    Priori SG. Exploring the hidden danger of noncardiac drugs. J Cardiovasc Electrophysiol 1998; 9: 1114–6PubMedCrossRefGoogle Scholar
  167. 167.
    Gupta PR, Somani PN, Avasthey P, et al. Prolonged QT and hypertrophic cardiomyopathy in two families with 10 sudden deaths. J Assoc Physicians India 1985; 33: 353–5PubMedGoogle Scholar
  168. 168.
    Martin AB, Garson Jr A, Perry JC. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J 1994; 127: 64–70PubMedCrossRefGoogle Scholar
  169. 169.
    Peters S, Rust H, Trummel M, et al. Familial hypertrophic cardiomyopathy associated with prolongation of the QT interval. Z Kardiol 2000; 89: 624–9PubMedCrossRefGoogle Scholar
  170. 170.
    Kaab S, Dixon J, Duc J, et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998; 98: 1383–93PubMedCrossRefGoogle Scholar
  171. 171.
    Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 1978; 57: 1074–7PubMedCrossRefGoogle Scholar
  172. 172.
    Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998; 338: 1709–14PubMedCrossRefGoogle Scholar
  173. 173.
    Veglio M, Sivieri R, Chinaglia A, et al. QT interval prolongation and mortality in type 1 diabetic patients: a 5-year cohort prospective study: Neuropathy Study Group of the Italian Society of the Study of Diabetes, Piemonte Affiliate. Diabetes Care 2000; 23: 1381–3PubMedCrossRefGoogle Scholar
  174. 174.
    Whitsel EA, Boyko EJ, Siscovick DS. Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care 2000; 23: 241–7PubMedCrossRefGoogle Scholar
  175. 175.
    Rossing P, Breum L, Major-Pedersen A, et al. Prolonged QTc interval predicts mortality in patients with type 1 diabetes mellitus. Diabet Med 2001; 18: 199–205PubMedCrossRefGoogle Scholar
  176. 176.
    Marques JL, George E, Peacey SR, et al. Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 1997; 14: 648–54PubMedCrossRefGoogle Scholar
  177. 177.
    Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27: 28–34PubMedCrossRefGoogle Scholar
  178. 178.
    Choy AM, Lang CC, Roden DM, et al. Abnormalities of the QT interval in primary disorders of autonomic failure. Am Heart J 1998; 136: 664–71PubMedCrossRefGoogle Scholar
  179. 179.
    Ishizaki F, Harada T, Yoshinaga H, et al. Prolonged QTc intervals in Parkinson’s disease: relation to sudden death and autonomic dysfunction [in Japanese]. No To Shinkei 1996; 48: 443–8PubMedGoogle Scholar
  180. 180.
    Kocheril AG, Bokhari SA, Batsford WP, et al. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997; 20: 2810–6PubMedCrossRefGoogle Scholar
  181. 181.
    Murata M, Tamai I, Sai Y, et al. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab Dispos 1998; 26: 1113–9PubMedGoogle Scholar
  182. 182.
    Bertino Jr JS, Owens Jr RC, Carnes TD, et al. Gatifloxacin-associated corrected QT interval prolongation, TdP, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002; 34: 861–3PubMedCrossRefGoogle Scholar
  183. 183.
    Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49: 593–6PubMedCrossRefGoogle Scholar
  184. 184.
    Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin. Pharmacotherapy 2001; 21: 1468–72PubMedCrossRefGoogle Scholar
  185. 185.
    Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003; 114: 135–41PubMedCrossRefGoogle Scholar
  186. 186.
    Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95). Committee for Proprietary Medicinal Products, London, 1997 Dec. Available from URL: http://www.emea.eu.int/htms/human/ewp/ewpfin.htm [Accessed 2003 Apr 15]
  187. 187.
    Abel S, Nichols DJ, Brearley CJ, et al. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 2000; 49: 64–71PubMedCrossRefGoogle Scholar
  188. 188.
    Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16: 408–14PubMedCrossRefGoogle Scholar
  189. 189.
    Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997; 51: 913–21PubMedGoogle Scholar
  190. 190.
    Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human mdr1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43: 285–307PubMedCrossRefGoogle Scholar
  191. 191.
    Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276: 35669–75PubMedCrossRefGoogle Scholar
  192. 192.
    Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302: 804–13PubMedCrossRefGoogle Scholar
  193. 193.
    Fulop G, Phillips RA, Shapiro AK, et al. ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 1987; 144: 673–5PubMedGoogle Scholar
  194. 194.
    Craft TM. Torsade de pointes after astemizole overdose [letter]. Br Med J (Clin Res Ed) 1986; 292: 660CrossRefGoogle Scholar
  195. 195.
    Zhou Z, Volperian VR, Gong Q, et al. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol 1999; 10: 836–43PubMedCrossRefGoogle Scholar
  196. 196.
    Cardiotoxicity of astemizole in overdose: dosing is critical. Committee on Safety of Medicines. London: Current Problems, 1987 Mar; 19: 1–2Google Scholar
  197. 197.
    Cross J, Lee H, Westelinck A, et al. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002; 11: 439–46PubMedCrossRefGoogle Scholar
  198. 198.
    Cohen JS. Dose discrepancies between the Physicians’ Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 2001; 161: 957–64PubMedCrossRefGoogle Scholar
  199. 199.
    Guidance on Pharmacokinetic Studies in Man (Eudra/C/87/013). In: The rules governing medicinal products in the European Union EudraLex. Vol. 3C. Guidelines-efficacy; Luxembourg: Office for Official Publications of the European Communities, 1998: 99 [online]. Available from URL: http://pharmacos.eudra.org/F2/eudralex/vol-3/pdfs-en/3cc3aen.pdf [Accessed 2003 Apr 15]
  200. 200.
    Note for Guidance on Ethnic Factors in the Acceptability of Foreign Clinical Data. (CPMP/ICH/289/95) Committee for Proprietary Medicinal Products, London, March 1998 [online]. Available from URL: http://www.emea.eu.int/htms/human/ich/efficacy/ichfin.htm [Accessed 2003 Apr 15]
  201. 201.
    Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98). Committee for Proprietary Medicinal Products, London, 2001 Jul [online]. Available from URL: http://www.emea.eu.int/htms/human/ewp/ewpfin.htm [Accessed 2003 Apr 15]
  202. 202.
    Guidance Note on Drug Metabolism/Drug Interaction Studies in the Drug Development Process. Studies in vitro. Food and Drug Administration Apr 1997 [online]. Available from URL: http://www.fda.gov/cder/guidance/index.htm [Accessed 2003 Apr 15]
  203. 203.
    Clinical pharmacokinetic studies of pharmaceuticals. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2001 JunGoogle Scholar
  204. 204.
    Methods of drug interaction studies. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2001 JunGoogle Scholar
  205. 205.
    Kaneko A, Lum JK, Yaviong L, et al. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 1999; 9: 581–90PubMedCrossRefGoogle Scholar
  206. 206.
    Iwasa H, Itoh T, Nagai R, et al. Twenty single nucleotide polymorphisms (SNPs) and their allelic frequencies in four genes that are responsible for familial long QT syndrome in the Japanese population. J Hum Genet 2000; 45: 182–3PubMedCrossRefGoogle Scholar
  207. 207.
    Iwasa H, Kurabayashi M, Nagai R, et al. Multiple single-nucleotide polymorphisms (SNPs) in the Japanese population in six candidate genes for long QT syndrome. J Hum Genet 2001; 46: 158–62PubMedCrossRefGoogle Scholar
  208. 208.
    Iwasa H, Kurabayashi M, Nagai R, et al. Twenty single-nucleotide polymorphisms in four genes encoding cardiac ion channels. J Hum Genet 2002; 47: 208–12PubMedCrossRefGoogle Scholar
  209. 209.
    Hiraoka M. Inherited arrhythmic disorders in Japan. J Cardiovasc Electrophysiol 2003; 14: 431–4PubMedCrossRefGoogle Scholar
  210. 210.
    Fukushige T, Yoshinaga M, Shimago A, et al. Effect of age and overweight on the QT interval and the prevalence of long QT syndrome in children. Am J Cardiol 2002; 89: 395–8PubMedCrossRefGoogle Scholar
  211. 211.
    Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667–71PubMedCrossRefGoogle Scholar
  212. 212.
    Sallustio BC, Westley IS, Morris RG. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 2002; 54: 107–14PubMedCrossRefGoogle Scholar
  213. 213.
    Hiratsuka M. Development of simplified and rapid detection assay for genetic polymorphisms influencing drug response and its clinical applications. [in Japanese] Yakugaku Zasshi 2002; 122: 451–63PubMedCrossRefGoogle Scholar
  214. 214.
    Verstuyft C, Morin S, Yang J, et al. Rapid and robust genotyping strategy for cytochrome P450 2C9 and MDR1 single nucleotide polymorphisms identification [in French]. Ann Biol Clin (Paris) 2003; 61: 305–9Google Scholar
  215. 215.
    Jongbloed R, Marcelis C, Velter C, et al. DHPLC analysis of potassium ion channel genes in congenital long QT syndrome. Hum Mutat 2002; 20: 382–91PubMedCrossRefGoogle Scholar
  216. 216.
    Murphy MP. Current pharmacogenomic approaches to clinical drug development. Pharmacogenomics 2000; 1: 115–23PubMedCrossRefGoogle Scholar
  217. 217.
    Murphy MP, Beaman ME, Clark LS, et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial [published erratum appears in Pharmacogenetics 2001; 11: 185]. Pharmacogenetics 2000; 10: 583–90PubMedCrossRefGoogle Scholar
  218. 218.
    Raschetti R, Maggini M, Da Cas R, et al. Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 2001; 285: 1840–1PubMedCrossRefGoogle Scholar
  219. 219.
    Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284: 3036–9PubMedCrossRefGoogle Scholar
  220. 220.
    Krasucki C, McFarlane F. Electrocardiograms, high-dose antipsychotic treatment and College guidelines. Psychiatric Bull 1996; 20: 326–30CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Medicines and Healthcare products Regulatory AgencyVauxhallUnited Kingdom

Personalised recommendations